C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript

· seekingalpha.com

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide June 18, 2026 9:00 AM...

Presentation

Operator Good day, and welcome to the educational KOL webinar [Operator Instructions]. Please note, this event is being recorded. I would now like...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI